Ameliorating effect of lipo-ATRA treatment on the expression of TIG3 and its suppressing effect on PPARγ gene expression in lung cancer animal model

This study aimed to find out the molecular therapeutic effect of lipo-ATRA on tumour suppressor TIG3 and cell proliferative biomarker PPAR gamma in B (a) P-induced lung cancer model. In RT-PCR study, ATRA- and lipo-ATRA-treated mice samples showed relatively higher TIG3 expression and decreased PPAR gamma expression (Band density) than cancer control. Among treatments, lipo-ATRA showed vital effect than free ATRA by enhancing TIG3 and decreasing PPAR gamma. The qPCR results also showed significant (p <= 0.05) difference in both TIG3 and PPAR (RQ values of TIG3, lipo-ATRA 23.85 +/- 1.29; free ATRA 10.43 +/- 1.81 and for PPAR gamma, lipo-ATRA 4.707 +/- 1.21; free ATRA 15.78 +/- 2.34). From this, we conclude that liposomal ATRA formulation is most preferable for prolonged delivery of ATRA at targeted site to favour molecular action. It implies that the therapeutic effect of lipo-ATRA in lung cancer was exhibited by ameliorating the TIG3 expression and by suppressing the expression of PPAR gamma.